• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research

Direct healthcare costs and cost-effectiveness of acute coronary syndromes secondary prevention with ticagrelor compared to clopidogrel - economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
CONCLUSIONS: In lifelong time horizon, which should be used in case of comparison of technologies with different impact on mortality, cost-effectiveness evaluation resulted in more favourable economic outcomes for ticagrelor than for generic clopidogrel with the cost per QALY well below recommended willingness to pay (WTP) threshold in Poland (24 965 PLN vs. 111 381 PLN). PMID: 24846362 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 20, 2014 Category: Cardiology Authors: Pawęska J, Macioch T, Perkowski P, Budaj A, Niewada M Tags: Kardiol Pol Source Type: research